Navigation Links
Novel technique switches triple-negative breast cancer cells to hormone-receptor positive cells
Date:11/1/2011

Within many hormone-receptor positive breast cancers lives a subpopulation of receptor-negative cells knock down the hormone-receptor positive cells with anti-estrogen drugs and you may inadvertently promote tumor takeover by more dangerous, receptor-negative cells. A study recently published in the Proceedings of the National Academy of Sciences describes how to switch these receptor-negative cells back to a state that can be targeted by existing hormone therapies.

"We found that these estrogen-receptor negative cells express high levels of a Notch receptor protein," says James Haughian, PhD, investigator at the University of Colorado Cancer Center and instructor at the University of Colorado School of Medicine. "And when you blockade this Notch activity, you end up with a pure population of hormone-receptor positive cells."

Very basically, within a breast cancer, you frequently have different kinds of cells living together some that have estrogen receptors and so need to "grab" estrogen in order to survive, grow and replicate. And, Haughian finds, some with similar Notch receptors that need to "grab" Notch proteins in order to survive, grow and replicate. On these cells without estrogen receptors but with Notch receptors, blockade this Notch pathway and the cell again becomes dependent on estrogen and thus likely treatable with anti-estrogen therapies.

"It's rare to get something that works so fantastically well as this," Haughian says.

Whether this switch from hormone-insensitive to hormone-sensitive is due to basic evolution killing the triple-negative cells leaves more resources for the growth of hormone-receptor positive cells or whether inhibiting Notch signaling, in fact, causes triple-negative cells to grow hormone receptors is still under investigation.

Whatever the precise mechanism, drugs that inhibit this Notch activity are already in clinical trials for breast cancer. However, Kathryn Horwitz, PhD, investigator at the CU Cancer Center and Distinguished Professor of Endocrinology at the University of Colorado School of Medicine theorizes that, "monotherapy with a Notch inhibitor might not be enough on its own, but may convert the cancer into a hormone-therapy treatable state."

This finding that Notch inhibition converts a triple-negative cancer subpopulation to a hormone-receptor positive population implies the potential usefulness of combination therapy perhaps a Notch inhibitor to make all the cancer's cells hormone-sensitive, followed by an anti-estrogen to treat them.

"Theorizing that and proving it is another matter," Horwitz says. "But if a clinician came knocking on our door, we'd say hey, let's try it."


'/>"/>
Contact: Garth Sundem
garth.sundem@ucdenver.edu
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. The Michael J. Fox Foundation awards nearly $200,000 to develop novel drugs for Parkinsons disease
2. Novel technique uses RNA interference to block inflammation
3. La Jolla Institute discovers novel mechanism for preventing infection via bodys mucosal borders
4. Novel drug combination offers therapeutic promise for hard-to-treat cancers
5. Novel approach scores first success against elusive cancer gene
6. Novel method for increasing antibiotic yields
7. Tropical coral could be used to create novel sunscreens for human use, say scientists
8. A novel mechanism that regulates pro-inflammatory cells is identified
9. Novel analysis by Allen Institute sheds new light on the mechanisms of brain development
10. Novel gene increases yeasts appetite for plant sugars
11. Life scientists use novel technique to produce genetic map for African Americans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
(Date:3/24/2017)... , March 24, 2017 The Controller General of ... Mr. Abdulla Algeen have received the prestigious international IAIR Award ... Continue Reading ... ... and Deputy Controller Abdulla Algeen (small picture on the right) have received ...
Breaking Biology News(10 mins):
(Date:7/15/2017)... , ... July 15, 2017 , ... Cuvette ... years. During this time, the people at FFS have learned that their biggest ... engineers at FFS are able to launch new products to meet the changing needs ...
(Date:7/14/2017)... ... July 13, 2017 , ... LGC Maine Standards ... received US FDA 510 (k) clearance for use on Siemens Sysmex® CS-2500 System ... VALIDATE® D-Dimer kit, prepared using the CLSI EP06-A “equal delta” sample preparation, offers ...
(Date:7/13/2017)... ... July 13, 2017 , ... Heritage Biologics is ... is the independent leader in promoting healthcare quality through accreditation, certification and measurement. ... care, improved processes and better patient outcomes. , “Achieving URAC accreditation is ...
(Date:7/13/2017)... ... July 13, 2017 , ... ... Inc. (FITCI), has experienced robust growth in the past year after an intensive ... launched several Entrepreneurial Acceleration Programs and expanded its board of directors to revitalize ...
Breaking Biology Technology: